Search Share Prices
AZN Headlines - AstraZeneca plc (LON:AZN) price target raised to GBX 6,400 by Morgan Stanley
Today, Morgan Stanley raised its price target on AstraZeneca plc (LON:AZN) to GBX 6,400 per share. There are 11 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
AstraZeneca (AZN) Rating Reiterated by Shore Capital
AstraZeneca (LON:AZN)‘s stock had its “hold” rating reiterated by stock analysts at Shore Capital in a report released on Friday. Several other equities research analysts have also recently weighed in ...
Credit Suisse Group Reiterates “GBX 6,350” Price Target for AstraZeneca (AZN)
AstraZeneca (LON:AZN) has been assigned a GBX 6,350 ($82.97) price objective by Credit Suisse Group in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharma...
AstraZeneca share price underperforms as Imfinzi disappoints in trial
Shares in AstraZeneca (LON:AZN) have fallen marginally into negative territory as the blue-chip group’s Imfinzi drug disappointed in a late-stage trial. The news marks another blow for the Anglo ...
AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial
One of AstraZeneca PLC’s (LON:AZN) key new drugs Imfinzi has failed in yet another late-stage clinical trial, this time in advanced head and neck cancer. The drug was tested both on its own and in com...